Laboratory of Immunological and Tumour Models

We elucidate interactions between tumour cells and the immune system and the therapeutic modulation of these interactions

+ experimental cancer therapy, + tumour immunology, + murine models, + JAK/STAT signalling, + cellular senescence

Milan Reiniš

Group leader

Scientific Career – Milestones

since 2019: Research Service Group Leader, IMG, Prague
2015-2018: Research Fellow, Czech Center for Phenogenomics, IMG, Prague
2005-2014: Research Group Leader, IMG, Prague
2000-2002: Postdoctoral Fellow, Wadsworth Center, NYS Department of Health, Albany, USA
1993: PhD, IMG, Prague

Immunology of MHC class I-deficient tumours

We have documented the epigenetic mechanisms of decreased surface expression of MHC class I molecules on tumour cells and proposed immunotherapy for MHC class I-deficient tumuors. [pubmed] [doi]

JAK/STAT signalling pathways in cancer and cellular senescence

We have investigated JAK/STAT signaling pathways (specifically IFNγ/STAT1 and IL-6/STAT3) and their balance in cellular stress, senescence, and cancer development and therapy. We also evaluated novel pSTAT3 inhibitors.[pubmed] [doi]

Proof of principle (immuno)therapeutic experiments using murine models

As part of collaborations and contract research, we have tested new therapeutic approaches and agents in murine cancer models, such as cellular vaccines, modified cytokines, or nanoparticles. [pubmed] [doi]

Research Reports

2020-2022 / 2017-2019 / 2013-2014 / 2011-2012 / 2009-2010 / 2008 / 2007

Additional information about group